1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Australia Pharmaceuticals and Healthcare Report Q4 2016

Australia Pharmaceuticals and Healthcare Report Q4 2016

  • September 2016
  • -
  • Business Monitor International
  • -
  • 98 pages

Includes 3 FREE quarterly updates

BMI View:

The incumbent Liberal-National coalition's victory in Australia's federal elections will not bringabout a clear policy direction for the healthcare sector. While the government has a fresh mandate to enactits policies, it is considerably weaker from the previous election and will be constrained by senate politicswhere the coalition does not have a majority. This creates downside risks for pharmaceutical firms keen tosee promises by the coalition, such as an investment of AUD7mn (USD5mn) into clinical research, frombeing implemented.

Headline Expenditure Projections


- Pharmaceuticals: AUD13.94bn (USD10.47bn) in 2015 to AUD14.39bn (USD10.49bn) in 2016; +3.2%in local currency terms and +0.2% in US dollar terms. US dollar forecast revised due to significantexchange rate fluctuations.

- Healthcare: AUD162.02bn (USD121.69bn) in 2015 to AUD168.94bn (USD123.24bn) in 2016; +4.3%in local currency terms and +1.3% in US dollar terms. US dollar forecast revised due to exchange ratefluctuations.

Table Of Contents

Australia Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Australia 2012-2020) 14
Healthcare Market Forecast 15
Table: Selected Health Measures In Australia FY2015/16 Budget 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2012-2020) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2012-2020) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Australia 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Australia 2012-2020) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Australia 2012-2020) 26
OTC Medicines Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Australia 2012-2020) 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (Australia 2014-2020) 31
Table: Pharmaceutical Trade Data And Forecasts local currency (Australia 2014-2020) 31
Industry Risk Reward Index 32
Asia Pacific Risk/Reward Index - Q4 2016 32
Australia Risk/Reward Index 39
Rewards 39
Risks 40
Regulatory Review 41
Table: EU and ICH Guidelines Adopted In The TGA's Biosimilars Guidance Document 42
Intellectual Property Issues 44
Pricing and Reimbursement Regime 48
Table: Selected Drugs Undergoing SPD (AUD) 49
Table: Historical PBS Co-Payments 51
Table: New PBS Formularies 53
Market Overview 54
Healthcare Sector 54
Research and Development 55
Clinical Trials 56
Epidemiology 57
Table: Estimated Number Of New Cases Of Cancer In Australia 60
Competitive Landscape 62
Research-Based Industry 62
Table: Multinational Market Activity 63
Pharmaceutical Distribution 64
Company Profile 66
Australian Pharmaceutical Industries 66
CSL 69
GlaxoSmithKline 73
Mayne Pharma Group 77
Sanofi 80
Sigma 83
Demographic Forecast 87
Table: Population Headline Indicators (Australia 1990-2025) 88
Table: Key Population Ratios (Australia 1990-2025) 88
Table: Urban/Rural Population and Life Expectancy (Australia 1990-2025) 89
Table: Population By Age Group (Australia 1990-2025) 89
Table: Population By Age Group % (Australia 1990-2025) 90
Glossary 92
Methodology 94
Pharmaceutical Expenditure Forecast Model 94
Healthcare Expenditure Forecast Model 94
Notes On Methodology 95
Risk/Reward Index Methodology 96
Index Overview 97
Table: Pharmaceutical Risk/Reward Index Indicators 97
Indicator Weightings 98

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.